Small-cell lung cancer (SCLC) has defied the scientific community for decades. Chemotherapy has been the mainstay treatment for patients with SCLC and, unlike its non-small-cell counterpart, no significant therapeutic breakthroughs have been made since the 1970s. Recently, new immunotherapeutic and targeted therapy options became available for these patients. In this article, the results obtained with these therapeutic strategies are briefly discussed.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
